mProX™ Human CDK17 Stable Cell Line

Sub Cat	Product Name	Target Protein Species	Host Cell Type	Assay Types	Inquiry	Datasheet
S01YF-1122-KX1063	Magic™ Human CDK17/p35NCK in Vitro Assay	Human		Kinase Assay

Product Information

Target Protein

CDK17

Target Family

Kinases/Enzyme Drug Discovery Assays and Products

Target Protein Species

Human

Host Cell Type

CHO-K1; HEK293

Target Classification

Kinase Cell Lines

Target Research Area

CNS Research; Reproductive Research

Related Diseases

Spastic Paraplegia 16, X-Linked and Spastic Paraplegia 12, Autosomal Dominant

Gene ID

5128

UniProt ID

Q00537

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

Kinase for serine/threonine proteins The PCTK2 gene in humans encodes the enzyme PCTAIRE-2. The protein that this gene encodes is a member of the protein kinase ser/thr family, specifically the cdc2/cdkx subfamily. Rat protein, which is assumed to have a function in terminally developed neurons, is comparable to it. Spastic Paraplegia 16, X-Linked, and Spastic Paraplegia 12, Autosomal Dominant are diseases linked to CDK17. This gene's Gene Ontology (GO) annotations include protein tyrosine kinase activity, transferase activity, and transferring phosphorus-containing groups. CDK16 is a significant paralog of this gene. The customized CDK17 stable cell line can be used in antibody discovery and development, potential drug candidate screening and signaling pathway researches.

Protocols

Please visit our protocols page.

Customer Reviews

chat Christopher

The CDK17 KO cell line was easy to use, and the support team was responsive to our inquiries. Jun 09 2023

chat Verified Customer

chat Kathleen

We used the CDK17 cell line for target validation in our drug development project, and it performed flawlessly. Oct 18 2022

chat Verified Customer

FAQ

Any questions about our products? Please visit our frequently asked questions page.

Published Data

Fig.1 Expression of CDK5, CDK11, CDK16, CDK17 and CDK18 mRNA in MIO-M1 cells.

A peak response was attained at 500 nM AG-012986, while a meaningful effect was attained at 200 nM in each case. About 25% was the maximum reduction in viability; complete toxicity was not seen. MIO-M1 cells showed very minimal expression of CDK18, but high expression of CDK5, 11, 16, and 17.

Ref: Wright, Phillip, et al. "Differential expression of cyclin-dependent kinases in the adult human retina in relation to CDK inhibitor retinotoxicity." Archives of Toxicology 93 (2019): 659-671.

Pubmed: 30617560

DOI: 10.1007/s00204-018-2376-8

Research Highlights

Independent factors included CDK13, PHF21A, and MTHFD2, according to regression analysis. According to the findings, CDK17, GNA13, PHF21A, and MTHFD2 may have significant functions and be useful in the diagnosis and management of gliomas.
Liu, Mingfa, et al. "The identification of key genes and pathways in glioma by bioinformatics analysis." Journal of Immunology Research 2017 (2017).
Pubmed: 29362722 DOI: 10.1155/2017/1278081